Aarti Drugs Limited AARTIDRUGS.NS · Stock Open Aarti Drugs Limited in new tab
Aarti Drugs Limited Analysis (AARTIDRUGS.NS)
Is Aarti Drugs Limited a good investment? Aarti Drugs Limited (AARTIDRUGS.NS) is currently trading at 428.50 INR.
In terms of valuation, the stock trades at a P/E ratio of 20.47. This valuation is generally in line with the broader market.
For income investors, Aarti Drugs Limited pays a dividend yield of 0.47%.
Investor FAQ
Does Aarti Drugs Limited pay a dividend?
Yes, it pays an annual dividend of 2.00 INR (0.47% yield).
What asset class is Aarti Drugs Limited?
Aarti Drugs Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.
| Year | Total Dividends |
|---|---|
| ▸2027 |
2.00 INR
|
| March 2, 2027 (estimated) | 2.0000 |
| ▸2026 |
2.00 INR
|
| March 4, 2026 | 2.0000 |
| ▸2025 |
1.00 INR
|
| Feb. 28, 2025 | 1.0000 |
| ▸2024 |
1.00 INR
|
| Feb. 23, 2024 | 1.0000 |
| ▸2023 |
1.00 INR
|
| Feb. 26, 2023 | 1.0000 |
| ▸2022 |
1.00 INR
|
| March 2, 2022 | 1.0000 |
| ▸2020 |
4.50 INR
|
| Nov. 22, 2020 | 2.5000 |
| Feb. 20, 2020 | 2.0000 |
| ▸2019 |
1.00 INR
|
| Aug. 12, 2019 | 1.0000 |
| ▸2018 |
1.00 INR
|
| Sept. 7, 2018 | 1.0000 |
| ▸2017 |
1.00 INR
|
| Sept. 15, 2017 | 1.0000 |
| ▸2016 |
4.50 INR
|
| March 31, 2016 | 3.0000 |
| Feb. 22, 2016 | 1.5000 |
| ▸2015 |
10.25 INR
|
| Nov. 20, 2015 | 2.2500 |
| Aug. 22, 2015 | 3.0000 |
| Feb. 10, 2015 | 5.0000 |
| ▸2014 |
15.00 INR
|
| Nov. 27, 2014 | 5.0000 |
| July 19, 2014 | 5.5000 |
| March 2, 2014 | 4.5000 |
| ▸2013 |
10.00 INR
|
| Nov. 25, 2013 | 3.0000 |
| Aug. 9, 2013 | 4.0000 |
| Feb. 16, 2013 | 3.0000 |
| ▸2012 |
8.00 INR
|
| Nov. 10, 2012 | 3.0000 |
| Sept. 5, 2012 | 3.0000 |
| Feb. 10, 2012 | 2.0000 |
| ▸2011 |
5.00 INR
|
| July 30, 2011 | 2.5000 |
| Feb. 15, 2011 | 2.5000 |
| ▸2010 |
5.00 INR
|
| Sept. 2, 2010 | 5.0000 |
| ▸2009 |
3.00 INR
|
| Aug. 7, 2009 | 3.0000 |
| ▸2008 |
1.80 INR
|
| Sept. 1, 2008 | 1.8000 |
| ▸2007 |
1.20 INR
|
| April 5, 2007 | 1.2000 |
| ▸2006 |
1.50 INR
|
| Aug. 5, 2006 | 1.5000 |
| ▸2005 |
1.60 INR
|
| Aug. 13, 2005 | 1.6000 |
| ▸2004 |
3.20 INR
|
| Nov. 21, 2004 | 1.4000 |
| July 14, 2004 | 1.8000 |
| ▸2003 |
1.20 INR
|
| Nov. 30, 2003 | 1.2000 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Aarti Drugs Limited | Mar 04, 2026 | Paid | 2.0 INR |
Community Discussion